Skip to content

Clinical Utility of the SPEAC® System: A Case Series

Clinical Utility of the SPEAC® System: A Case Series

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03484598
Enrollment
26
Registered
2018-04-02
Start date
2018-09-01
Completion date
2020-04-30
Last updated
2019-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Brief summary

The primary objective is to collect preliminary data related to the clinical utility of the SPEAC System in patients with a history of motor seizures. This trial is primarily an observational investigation. This protocol describes a series of observational case studies. Each case study is intended to be interpreted independent from the other case studies. Self-reported seizure frequency will be compared to observed seizure frequency using the SPEAC System.

Interventions

A lightweight, non-invasive monitor that is placed on the belly of the biceps muscles to analyze surface electromyography (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures. It provides an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.

Sponsors

Brain Sentinel
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Subject has a reported history of motor seizures (epileptic or not or unknown) with upper extremity motor involvement. * The subject's first reported seizure must be within the last 5 years. * Male or Female between the ages 22 and 99. * If female and of childbearing potential, subject must agree to not become pregnant during the trial. * Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments. * Subject or Primary Caregiver must be competent to follow all study procedures. * Subject must be willing to use the Seizure Monitoring and Alerting System for a long period of time (up to 90 days), for a minimum of 30 hours/ week.

Exclusion criteria

* The subject cannot be pregnant, or nursing. * The subject cannot be sensitive or allergic to adhesives or tapes.

Design outcomes

Primary

MeasureTime frameDescription
Compare Seizure Frequency1 yearWe will compare self-reported seizure frequency to the seizure frequency measured by the SPEAC System.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026